JACC:TAVR老年患者的习惯性体力活动

2019-04-21 xiangting MedSci原创

久坐不动的患者TAVR术后死亡率和功能下降的风险较高。

这项研究旨在评估经导管主动脉瓣置换术(TAVR)老年患者习惯性体力活动(HPA)的分布和预后意义。

在社区居住的老年人中,低HPA与死亡率和残疾有关。在TAVR的情况下,低HPA是否为下游发病的危险因素或是严重主动脉瓣狭窄的副产物并可在矫正后有所改善,尚不清楚。

对前瞻性多中心FRAILTY-AVR研究(主动脉瓣置换术中的虚弱性)接受TAVR的老年人进行采访,在基线和随访时使用有效问卷将HPA量化为千卡/周。主要终点是12个月时的全因死亡率。

该队列包括755名患者,中位年龄84.0岁(四分位距[IQR]:80.0至87.0岁)。在基线时,中位HPA为1,116千卡/周(IQR:227至2,715千卡/周),73%的患者每周中度或剧烈HPA<150分钟。久坐不动的患者更可能是老年、女性、体弱、认知受损、抑郁和伴多发合并症,尽管其左心室功能和主动脉瓣狭窄严重程度相似。在调整这些协变量的logistic回归模型中,HPA与12个月的死亡率相关(优势比:0.84/100kcal; 95%置信区间:0.73至0.98)。HPA与较长的住院时间、出院后到医疗机构和残疾相关。在12个月时,幸存者HPA的中位数为933千卡/周(IQR:0至2,334千卡/周),此前存在虚弱可以独立预测TAVR后的HPA恶化。

久坐不动的患者TAVR术后死亡率和功能下降的风险较高。

原始出处:
Janarthanan Sathananthan. Habitual Physical Activity in Older Adults Undergoing TAVR. JACC:Cardiovascular Interventions. 22 April 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854365, encodeId=7aed1854365cf, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Feb 04 07:14:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086363, encodeId=0fda20863638a, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Mon Sep 23 09:14:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326186, encodeId=c16a1326186bc, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Apr 23 01:14:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365078, encodeId=921e3650e874, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Apr 22 17:12:15 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
    2020-02-04 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854365, encodeId=7aed1854365cf, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Feb 04 07:14:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086363, encodeId=0fda20863638a, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Mon Sep 23 09:14:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326186, encodeId=c16a1326186bc, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Apr 23 01:14:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365078, encodeId=921e3650e874, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Apr 22 17:12:15 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854365, encodeId=7aed1854365cf, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Feb 04 07:14:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086363, encodeId=0fda20863638a, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Mon Sep 23 09:14:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326186, encodeId=c16a1326186bc, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Apr 23 01:14:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365078, encodeId=921e3650e874, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Apr 22 17:12:15 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854365, encodeId=7aed1854365cf, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Feb 04 07:14:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086363, encodeId=0fda20863638a, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Mon Sep 23 09:14:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326186, encodeId=c16a1326186bc, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Apr 23 01:14:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365078, encodeId=921e3650e874, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Apr 22 17:12:15 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
    2019-04-22 一个字-牛

    学习了谢谢分享

    0

相关资讯

JAMA Cardiol:主动脉瓣狭窄患者心脏结构和功能改变与TAVR结局的关联

主动脉瓣狭窄分期显示心脏变化的程度与TAVR后全因死亡率之间存在强烈的分级关联。

JACC:低危患者的经导管主动脉瓣置换术

1年时,低危症状性严重AS患者的TAVR是安全的。30天时在少数TAVR患者中观察到低密度小叶增厚,但并不影响长期的瓣膜血流动力学。

JACC:评估一种新型自扩张经导管心脏瓣膜CENTERA-EU试验的1年结局

CENTERA-EU试验证明了CENTERA THV的中期安全性和疗效。

Ann Thorac Surg:胸外科年鉴研究称,无症状严重主动脉瓣狭窄患者应尽早期手术

在《胸外科年鉴》上的一项新研究,无症状的严重主动脉瓣狭窄患者可能会从早期瓣膜置换的积极策略中获益,预后优于保守治疗。

JACC:TAVR对严重主动脉瓣狭窄患者住院率的影响

严重主动脉瓣狭窄(AS)患者的再住院率较高。本研究的目的旨在评估经导管主动脉瓣置换术(TAVR)对严重AS患者再住院率的影响。本研究纳入了15324名接受TAVR治疗的患者,平均年龄为84岁,平均胸外科医师学会预测死亡率风险评分为7.0,61.1%的患者是通过经股途径接受TAVR。与接受TAVR治疗之前相比,接受TAVR治疗后的心衰住院率和住院天数均有所下降。然而,全因、非心血管和出血住院率和住院

JAHA:经导管与外科主动脉瓣置换术院内结局的风险调整比较

在临床实践中TF-TAVR对于手术风险升高、年龄>80岁、NYHA-III/IV级和肾衰的患者具有优势。